Read by QxMD icon Read

"proton therapy"

Yuming Wan, Jing Huang, Feng Xu
A few study has proven that about 90% of local control rates might be benefit from stereotactic body radiotherapy (SBRT) for patients with medically inoperable stage I non-small cell lung cancer (NSCLC), it is reported SBRT associated overall survival and tumor specific survival is comparable with those treated with surgery. SBRT has been accepted as the first line treatment for inoperable patients with peripheral located stage I NSCLC. However, the role of SBRT in centrally located lesions is controversial for potential toxic effects from the adjacent anatomical structure...
May 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
Sonja M Schellhammer, Sebastian Gantz, Armin Lühr, Bradley M Oborn, Michael Bussmann, Aswin L Hoffmann
PURPOSE: Given its sensitivity to anatomical variations, proton therapy is expected to benefit greatly from integration with magnetic resonance imaging for on-line anatomy monitoring during irradiation. Such an integration raises several challenges, as both systems mutually interact. The proton beam will experience quasi-continuous energy loss and energy-dependent electromagnetic deflection at the same time, giving rise to a deflected beam trajectory and an altered dose distribution with a displaced Bragg peak...
May 15, 2018: Medical Physics
Daniel Sanchez-Parcerisa, Jose Udías
Open-source, MATLAB-based treatment planning systems FoCa and matRAD were used in a pilot project for training prospective medical physicists and postgraduate physics students in treatment planning and beam modeling techniques for proton therapy. In the four exercises designed, students learnt how proton pencil beams are modeled and how dose is calculated in three-dimensional voxelized geometries, how pencil beam scanning plans (PBS) are constructed, the rationale behind the choice of spot spacing in patient plans, and the dosimetric differences between photon IMRT and proton PBS plans...
May 12, 2018: Journal of Applied Clinical Medical Physics
Narayan Sahoo, Falk Poenisch, Xiaodong Zhang, Yupeng Li, MingFu Lii, Heng Li, Archana S Gautam, Richard Wu, Michael Gillin, Xiaorong R Zhu
The capabilities of the Eclipse treatment planning system (TPS) (Varian Medical Systems, Palo Alto, CA) for proton therapy treatment planning are described. Various steps involved in the planning process to produce a 3-dimensional (3D) dose distribution both for the passive scattering and pencil beam scanning proton beam therapy are outlined. Mitigation of range and setup uncertainties through robust optimization is discussed. Use of verification plans for patient treatment field dosimetry quality assurance (QA) is presented...
July 2018: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
Jeong Il Yu, Changhoon Choi, Sung-Won Shin, Arang Son, Ga-Haeng Lee, Shin-Yeong Kim, Hee Chul Park
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
May 10, 2018: Scientific Reports
Ramesh Rengan, Mary Redman, Jing Zeng
No abstract text is available yet for this article.
May 10, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Joseph K Kim, Jonathan E Leeman, Nadeem Riaz, Sean McBride, Chiaojung Jillian Tsai, Nancy Y Lee
The application of proton beam radiation therapy in the treatment of head and neck cancer has grown tremendously in the past few years. Globally, widespread interest in proton beam therapy has led to multiple research efforts regarding its therapeutic value and cost-effectiveness. The current standard of care using modern photon radiation technology has demonstrated excellent treatment outcomes, yet there are some situations where disease control remains suboptimal with the potential for detrimental acute and chronic toxicities...
May 9, 2018: Current Treatment Options in Oncology
Safia K Ahmed, Paul D Brown, Robert L Foote
The physical characteristics of proton therapy result in steeper dose gradients and superior dose conformality compared to photon therapy. These properties render proton therapy ideal for skull base tumors requiring dose escalation for optimal tumor control, and may also be beneficial for brain tumors as a means of mitigating radiation-related adverse effects. This review summarizes the literature regarding the role of proton therapy compared to photon therapy in the treatment of adult brain and skull base tumors...
April 2018: Seminars in Radiation Oncology
Jan Unkelbach, Harald Paganetti
Accurate prediction of tumor control and toxicities in radiation therapy faces many uncertainties. Besides interpatient variability in the response to radiation, there are also dosimetric uncertainties, that is, differences between the dose displayed in a treatment planning system and the dose actually delivered to the patient. These uncertainties originate from several sources including imperfect knowledge of the patient geometry, approximation in the physics of radiation interaction with tissues, and uncertainties in the biological effectiveness of radiation...
April 2018: Seminars in Radiation Oncology
Johannes A Langendijk, Liesbeth J Boersma, Coen R N Rasch, Marco van Vulpen, Johannes B Reitsma, Arjen van der Schaaf, Ewoud Schuit
The favorable beam properties of protons can be translated into clinical benefits by target dose escalation to improve local control without enhancing unacceptable radiation toxicity or to spare normal tissues to prevent radiation-induced side effects without jeopardizing local tumor control. For the clinical validation of the added value of protons to improve local control, randomized controlled trials are required. For the clinical validation of the added value of protons to prevent side effects, both model-based validation or randomized controlled trials can be used...
April 2018: Seminars in Radiation Oncology
Jacobus Maarten Schippers, Anthony Lomax, Adriano Garonna, Katia Parodi
In recent years there has been increasing interest in the more extensive application of proton therapy in a clinical and preferably hospital-based environment. However, broader adoption of proton therapy has been hindered by the costs of treatment, which are still much higher than those in advanced photon therapy. This article presents an overview of on-going technical developments, which have a reduction of the capital investment or operational costs either as a major goal or as a potential outcome. Developments in instrumentation for proton therapy, such as gantries and accelerators, as well as facility layout and efficiency in treatment logistics will be discussed in this context...
April 2018: Seminars in Radiation Oncology
Ann C Raldow, Theodore S Hong
Gastrointestinal malignancies inherently arise amidst visceral organs that are very radiation sensitive. While radiation therapy is an integral part of cancer treatment, its use has historically been limited by normal tissue toxicity. Proton therapy is a form of external-beam radiation associated with several dosimetric advantages as compared to photon therapy. Proton radiation may allow for the delivery of tumoricidal doses while minimizing side effects by decreasing the dose to adjacent organs at risk. We discuss the rationale for and challenges of using protons in the treatment of gastrointestinal cancers...
April 2018: Seminars in Radiation Oncology
Zhongxing Liao, Saumil J Gandhi, Steven H Lin, Jeffrey Bradley
The finite range of proton beams in tissues offers unique dosimetric advantages that theoretically allow dose to the target to be escalated while minimizing exposure of surrounding tissues and thus minimizing radiation-induced toxicity. This theoretical advantage has led to widespread adoption of proton therapy around the world for a wide variety of tumors at different anatomical sites. Many treatment-planning comparisons have shown that proton therapy has substantial dosimetric advantages over conventional radiotherapy...
April 2018: Seminars in Radiation Oncology
Steven J Frank, Pierre Blanchard, J Jack Lee, Erich M Sturgis, Merrill S Kies, Mitchell Machtay, Bhadrasain Vikram, Adam S Garden, David I Rosenthal, G Brandon Gunn, C David Fuller, Katherine Hutcheson, Stephen Lai, Paul M Busse, Nancy Y Lee, Alexander Lin, Robert L Foote
Intensity-modulated proton therapy minimizes the incidental irradiation of normal tissues in patients with head and neck cancer relative to intensity-modulated photon (x-ray) therapy and has been associated with lesser treatment-related toxicity and improved quality of life. A phase II/III randomized trial sponsored by the US National Cancer Institute is currently underway to compare deintensification treatment strategies with intensity-modulated proton therapy vs intensity-modulated photon (x-ray) therapy for patients with advanced-stage oropharyngeal tumors...
April 2018: Seminars in Radiation Oncology
Matthew D Hall, Julie A Bradley, Ronny L Rotondo, Ricardo Hanel, Chetan Shah, Christopher G Morris, Philipp R Aldana, Daniel J Indelicato
PURPOSE: To estimate the rate of and identify risk factors for vasculopathy after proton therapy in pediatric patients with central nervous system and skull base tumors. METHODS AND MATERIALS: Between 2006 and 2015, 644 pediatric patients with central nervous system and skull base tumors were treated with proton therapy at a single institution. The 3 most common histologies were craniopharyngioma (n = 135), ependymoma (n = 135), and low-grade glioma (n = 131)...
March 29, 2018: International Journal of Radiation Oncology, Biology, Physics
V De Smet, R Labarbe, F Vander Stappen, B Macq, E Sterpin
PURPOSE: In proton therapy planning, the accuracy of the Stopping Power Ratios (SPR) calculated in the stoichiometric CT calibration is affected by, amongst others, uncertainties on the mean excitation energies (I-values) of human tissues and water. Traditionally, the contribution of these uncertainties on the SPR have been conservatively estimated of the order of 1% or more for a reference tissue of known composition. This study provides a methodology that enables a finer estimation of this uncertainty, eventually showing that the traditional estimates of the uncertainty are too conservative...
May 4, 2018: Medical Physics
William M Mendenhall, Gail Sarto, Curtis M Bryant, Christopher G Morris, Christopher R Williams, Joseph A Costa, Mark Bandyk, Bradford S Hoppe, Randal H Henderson, R Charles Nichols, Nancy P Mendenhall
PURPOSE: Placement of fiducial markers for prostate radiotherapy (RT) is associated with a 2% to 3% risk of bacterial urinary tract infection (UTI) that may progress to sepsis necessitating hospitalization. These bacterial UTIs are primarily due to flouroquinolone (FQ) resistant Escherichia coli (E. coli). The incidence of this complication has increased in recent years. The purpose of this study is to determine whether rectal culture and sensitivity (C&S) to identify FQ resistant E...
May 4, 2018: American Journal of Clinical Oncology
Drosoula Giantsoudi, Judith Adams, Shannon MacDonald, Harald Paganetti
PURPOSE: To investigate the effect of differences in linear energy transfer (LET) and thus the relative biological effectiveness (RBE) between passively scattered proton therapy (PS) and pencil-beam scanning intensity-modulated proton therapy (IMPT). METHODS: IMPT treatment plans were generated for six ependymoma patients, originally treated with PS, using the original plan's computed tomography image sets and beam directions, and its dose-volume values as optimization constraints...
May 4, 2018: Acta Oncologica
Tereza Hanušová, Kamila Johnová, Matěj Navrátil, Jiří Valenta, Lutz Müller
Activation of detectors and phantoms used for commissioning and quality assurance of clinical proton beams may lead to radiation protection issues. Good understanding of the activation nuclide vectors involved is necessary to assess radiation risk for the personnel working with these devices on a daily basis or to fulfill legal requirements regarding transport of radioactive material and its release to the public. Eleven devices and material samples were irradiated with a 220 MeV proton pencil beam (PBS, Proton Therapy Center, Prague)...
May 4, 2018: Physics in Medicine and Biology
Sang Hee Ahn, Nohyun Lee, Changhoon Choi, Sung Won Shin, Youngyih Han, Hee Chul Park
We investigated the feasibility of using multifunctional Fe3O4/TaOx (core/shell) nanoparticles, developed for use in contrast agents for computed tomography (CT) and magnetic resonance imaging (MRI), as dose-enhancing radiosensitizers. First, to verify the detectability of Fe3O4/TaOx nanoparticles in imaging, in vivo tests were conducted. Approximately 600 mg/kg of 19-nm-diameter Fe3O4/TaOx nanoparticles dispersed in phosphate-buffered saline was injected into the tail vein of six Balb/c mice used as tumour (4T1 mammary carcinoma cell) models...
May 4, 2018: Physics in Medicine and Biology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"